An experimental one-time gene edit is showing striking and long-lasting drops in LDL cholesterol in an early human trial, while Cleveland researchers say a basic brain chemical may be quietly steering how genes are spliced in Alzheimer’s disease. Together, the findings are stirring up big questions about how we might prevent heart attacks and slow neurodegeneration, even as doctors keep reminding patients not to treat over-the-counter supplements like harmless candy.
One-Time Gene Edit Slashes LDL In Early Human Trial
Eli Lilly reported interim Phase 1b Heart-2 results showing its base editor VERVE-102, given as a single intravenous infusion, reduced circulating PCSK9 by up to 88% and lowered LDL-C by as much as 62% in the highest dose cohort, with reductions sustained in some patients for up to 18 months, according to Eli Lilly. The open-label interim analysis enrolled 35 adults across six ascending dose cohorts and reported no treatment-related serious adverse events. Lilly said it will move the program into a larger Phase 2 study later this year and that participants will be enrolled in long-term follow-up studies as part of the program.
Why A Single Infusion Could Rewrite Cholesterol Care
Clinicians note one reason the one-and-done idea is so compelling: persistence on chronic lipid therapy is uneven, with real-world studies showing substantial drop-off in the months after initiation, a problem that limits the population benefit of daily or repeated treatments. As one recent review found, adherence and persistence after starting lipid-lowering therapy vary widely and many patients do not remain on therapy long enough to gain full protection. The VERVE programs originated at Verve Therapeutics and were folded into Lilly’s pipeline after Lilly’s 2025 acquisition of Verve; regulators and sponsors also plan long-term safety monitoring for genome-editing products.
Nitric Oxide Acts As Splicing Switch In Alzheimer’s Brains
Separately, researchers at University Hospitals and Case Western Reserve published findings in Molecular Cell showing that nitric oxide broadly regulates alternative splicing in the brain and that levels of S-nitrosylated splicing proteins are reduced in Alzheimer’s disease. The team identified enzymes that remove nitric oxide from RNA-binding proteins, linked reduced nitric-oxide regulation to greater plaque accumulation and faster memory decline, and suggested that blocking those enzymes could restore healthy splicing, with plans underway for animal studies of new inhibitor classes. University Hospitals’ summary of the work frames the discovery as a challenge to the older idea that excess nitric oxide simply drives neurodegeneration.
Doctors To Patients: Be Careful With Supplements
Amid the scientific excitement, clinicians reminded the public that dietary supplements are regulated differently from drugs, and manufacturers do not have to demonstrate safety or effectiveness before marketing, a point the FDA outlines in its guidance on supplements. Health experts note supplements can interact with prescription medicines, carry risks for pregnant people, and, in high or unregulated doses, may stress the liver or kidneys. Cleveland Clinic physicians advise patients to “treat supplements like medications” and to discuss any routine supplements with their clinician, especially during pregnancy or when taking multiple prescriptions.
What To Watch Next
Researchers and companies say the immediate next steps are straightforward: larger, controlled trials for the PCSK9 base-editing program and preclinical testing of enzyme inhibitors that might restore nitric-oxide signaling in the brain. Lilly has said Phase 2 enrollment for VERVE-102 is planned later this year, and the Cleveland team is preparing animal studies to test inhibitor candidates and probe safety and efficacy in models. For patients, experts emphasize that these results are early but promising, and that decisions about stopping or replacing proven therapies should always be made with a clinician.
